Cerus Corporation closed a new debt facility with MidCap Financial providing up to $110 million [1].

This financing agreement allows the company to bolster its liquidity and manage operational costs through a structured loan. Access to such capital is critical for biotechnology firms to sustain research and development cycles without relying solely on equity markets.

The agreement was finalized on June 8, 2024 [1]. According to company reports, the facility consists of a term loan with a duration of five years [2].

While some reports have cited different figures for the facility, the primary financial records indicate the total amount available is up to $110 million [1]. The partnership with MidCap Financial establishes a specific credit line that the company can draw upon to meet its financial obligations over the next five years.

This move represents a strategic shift in how the company manages its debt load. By securing a multi-year term loan, Cerus Corporation avoids the immediate volatility of short-term credit markets, providing a more stable financial foundation for its ongoing corporate initiatives.

Details regarding the specific interest rates or covenants of the loan were not disclosed in the primary announcement. However, the five-year term [2] suggests a long-term approach to capital management rather than a temporary bridge loan.

“Cerus Corporation closed a new debt facility with MidCap Financial providing up to $110 million.”

The securing of a $110 million debt facility indicates that Cerus Corporation is prioritizing liquidity and long-term capital stability. By opting for a five-year term loan rather than short-term financing, the company is hedging against potential interest rate fluctuations and ensuring a predictable runway for its operational expenses.